Literature DB >> 9313323

Role of RigiScan in the etiologic differential diagnosis of erectile dysfunction.

T Karadeniz1, M Topsakal, A Aydogmus, M Beksan.   

Abstract

OBJECTIVE: The aim of this prospective study was to assess the reliability of nocturnal penile tumescence monitoring by an ambulatory RigiScan device in the etiological diagnosis of erectile dysfunction. PATIENTS AND METHODS: A total of 64 randomized patients with a complaint of impotence for at least 6 months initially underwent nocturnal penile tumescence rigidity (NPTR) monitoring on 2 consecutive nights in a private setting as session 1. All subjects then underwent a comprehensive multidisciplinary diagnostic approach including dynamic color Doppler sonography and pharmaco-cavernosometry as a second session in a blind fashion. The results of both sessions were compared with each other.
RESULTS: Sensitivity, specificity, positive predictive value and accuracy rate of NPTR monitoring in discriminating organic from psychogenic impotence with respect to a multidisciplinary diagnostic approach using sophisticated techniques were as 80.9, 81.8, 89.4 and 81.2%, respectively.
CONCLUSION: Although RigiScan differentiates organic from psychogenic impotence with a relatively high sensitivity, a multidisciplinary diagnostic approach is mandatory in establishing the ultimate diagnosis.

Entities:  

Mesh:

Year:  1997        PMID: 9313323     DOI: 10.1159/000283015

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  2 in total

1.  Erectile dysfunction after transurethral resection of the prostate: incidence and risk factors.

Authors:  Akmal Taher
Journal:  World J Urol       Date:  2004-10-16       Impact factor: 4.226

2.  Assessment of the American Joint Committee on Cancer staging (sixth and seventh editions) for clinically localized prostate cancer treated with external beam radiotherapy and comparison with the National Comprehensive Cancer Network risk-stratification method.

Authors:  Nicholas G Zaorsky; Tianyu Li; Karthik Devarajan; Eric M Horwitz; Mark K Buyyounouski
Journal:  Cancer       Date:  2012-04-27       Impact factor: 6.860

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.